BVNRY:OTC-Bavarian Nordic A/S (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 11.00

Change

0.00 (0.00)%

Market Cap

USD 1.77B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox and monkey pox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola; MVA-BN HPV that is in Phase I clinical trials to treat human papillomavirus; MVA-BN WEV, which is in Phase I clinical trials to treat equine encephalitis; and BN-Brachyury that is in Phase II clinical trials for the treatment of chordoma. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Hellerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.99 (-1.43%)

USD163.60B 24.44 2.74
CMXHF CSL Limited

+1.27 (+0.61%)

USD97.05B 42.41 25.71
CSLLY CSL Limited

+0.31 (+0.29%)

USD95.50B 43.19 25.71
GNMSF Genmab A/S

+10.89 (+3.03%)

USD23.27B 25.97 2.87
UCBJF UCB SA

N/A

USD22.12B 25.26 18.36
UCBJY UCB SA

-0.21 (-0.36%)

USD21.81B 24.87 18.36
SBHMY Sino Biopharmaceutical Limited

+0.39 (+1.79%)

USD21.38B 56.11 3.56
SBMFF Sino Biopharmaceutical Limited

+0.02 (+1.81%)

USD20.54B 59.30 3.56
PPTDF PeptiDream Inc

N/A

USD5.14B 260.99 1.35
MPSYF MorphoSys AG

N/A

USD4.05B 32.65 26.09

ETFs Containing BVNRY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.89% 58% F 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.89% 58% F 72% C-
Trailing 12 Months  
Capital Gain 23.11% 55% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.11% 55% F 70% C-
Trailing 5 Years  
Capital Gain -25.73% 57% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.73% 56% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain -3.13% N/A N/A 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.13% N/A N/A 31% F
Risk Return Profile  
Volatility (Standard Deviation) 36.25% N/A N/A 50% F
Risk Adjusted Return -8.63% N/A N/A 35% F
Market Capitalization 1.77B 92% A- 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.10 44% F 37% F
Price/Book Ratio 2.33 73% C 38% F
Price / Cash Flow Ratio -6.42 62% D- 80% B-
EV/EBITDA 1.90 55% F 56% F
Management Effectiveness  
Return on Equity 13.28% 88% B+ 83% B
Return on Invested Capital -10.23% 54% F 26% F
Return on Assets 5.69% 94% A 88% B+
Debt to Equity Ratio 21.20% 30% F 57% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.49 26% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector